KDM6A mutant cells showed decreased levels of IRF4 and c-MYC and were more sensitive to the inhibition of the histone methyltransferase EZH2 in vitro, suggesting a potential therapeutic role of EZH2 inhibitors in KDM6A-mutated MM [90]. This evidence concerns the gene MYC and Miyoshi myopathy.